<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102257</url>
  </required_header>
  <id_info>
    <org_study_id>05-1099</org_study_id>
    <secondary_id>1R34EY017626</secondary_id>
    <nct_id>NCT01102257</nct_id>
  </id_info>
  <brief_title>Dry Eye Assessment and Management: Feasibility Study</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Clinical Trial of Essential Fatty Acids for Dry Eye Disease: Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asbell, Penny, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Asbell, Penny, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a protocol investigating the efficacy of omega-3 fatty
      acids in treating dry eye disease. The study is termed &quot;feasibility&quot; because its purpose is
      to demonstrate an ability to execute the proposed protocol with compliance at two sites
      rather than generate statistically relevant data concerning the safety and efficacy of the
      supplement in patients with dry eye disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye disease (DED) is a common but often inadequately treated disease of the tears and
      surface of the eye. It can cause poor vision and chronic pain and is more frequent with
      increasing age. Inflammation may be an important component of this disease. This is supported
      by the observation that cyclosporine, a drug that targets the immune system, is approved for
      and effectively treats DED. Inflammatory processes likely produce ocular surface damage and
      contribute to chronic DED. Because not all people with DED respond to current
      anti-inflammatory treatments, other immune-modulating treatments would be of value.
      Furthermore, despite a great deal of evidence supporting DED as an inflammatory disease, not
      all researchers currently agree with this classification. More data that specifically
      measures inflammatory responses in DED needs to be collected in a well-characterized patient
      population and correlated with signs and symptoms of DED in order to improve our
      understanding and classification of the disease.

      Essential Fatty Acids (EFA) have been shown to diminish inflammatory responses in many human
      inflammatory diseases, and interest in the use of omega-3 and omega-6 fatty acids for disease
      treatment has resulted in several small studies as well as the use (and over-the-counter
      availability) of EFA-containing nutritional supplements, including several specifically for
      the treatment of DED. Despite this interest in EFA for DED, there are no strong empirical
      data from a well-controlled randomized controlled trial RCT supporting the use of EFA for
      DED. We postulate that DED is an inflammatory disease and hypothesize that EFA can mediate
      immune responses, thus improving DED signs, symptoms and associated measures of inflammation.
      The proposed three month feasibility study allows us the chance to demonstrate our ability to
      successfully execute our own protocol with compliance from the study patients before we begin
      the process of initiating a full-scale multi-center trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content</measure>
    <time_frame>Baseline and 3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Brief Ocular Discomfort Inventory (BODI)</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Impact of Dry Eye on Everyday Life (IDEEL)</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Associated With Chronic Pain</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ocular Surface</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Schirmer's</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Relevant Biomarkers: HLA-DR, MUC 5A, Cytokines</measure>
    <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Omega-3 EFA Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:
2000 mg EPA 1000 mg DHA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 EFA Supplement</intervention_name>
    <description>The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:
2000 mg EPA 1000 mg DHA</description>
    <arm_group_label>Omega-3 EFA Supplement</arm_group_label>
    <other_name>Fish oil supplements</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olive Oil</intervention_name>
    <description>Placebo group will take 5 capsules a day containing 3.0 grams of olive oil</description>
    <arm_group_label>Olive Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign and date the informed consent form approved by the IRB.

          2. ≥ 18 years of age

          3. Demonstrate at least 2 of the 4 following signs in the same eye at two consecutive
             visits (Visit 1: 7 - 21 days prior to randomization, and Visit 2: day of
             randomization).

               1. Conjunctival staining present ≥ 1

               2. Corneal fluorescein staining present ≥ 1

               3. Tear film break up time (TFBUT) ≤ 7 seconds

               4. Schirmer test ≤ 7 mm/5min

          4. Demonstrate symptoms of dry eye disease (OSDI score of at least 22 at screening visit
             and at least 15 at randomization visit).

          5. Use or desire to use artificial tears on average of 2 times per day in the 2 weeks
             preceding study entry (run in period). No newly diagnosed patients can be enrolled and
             if a new patient wants to participate, she/he must be put on tears and re-evaluated in
             6 months.

          6. Intraocular pressure (IOP) ≥ 5 mmHg and ≤ 22 mmHg in each eye.

          7. Women of child-bearing potential must agree to use a reliable method of contraception
             during study participation, and must demonstrate a negative urine pregnancy test at
             screening visit.

          8. Be willing/able to return for all study visits and to follow instructions from the
             study investigator and his/her staff.

          9. Be able to swallow large, soft gelcaps

        Exclusion Criteria:

          1. Patients who are allergic to ingredients of the active or placebo pills (fish, olive
             oil).

          2. Current diagnosis of ocular infection (e.g. bacterial, viral or fungal).

          3. History of ocular herpetic keratitis.

          4. Eye surgery (including cataract surgery) within 6 months prior to randomization.

          5. Previous LASIK surgery

          6. Pregnant or nursing/lactating

          7. Participation in a study of an investigational drug or device within the past 30 days.

          8. Recent (≤ 3 months) initiation of use of systemic corticosteroids or other
             immunosuppressive agent and/or is planning to change treatment during study
             participation

          9. Cognitive or psychiatric deficit that precludes informed consent or ability to perform
             requirements of the investigation.

         10. Contact lens wearers

         11. Use of glaucoma medication or history of surgery for glaucoma.

         12. Recent (≤ 3 months) insertion of punctual plugs.

         13. Using punctual plugs but unwilling to commit to their use for the duration of the
             study.

         14. Unwilling to commit to same brand of artificial tears throughout the study.

         15. Current use of EPA/DHA supplements in excess of 1 gram/day.

         16. Recent (≤ 6 months) initiation of use of Restasis.

         17. Use of Restasis but unwilling to commit to use of Restasis for the duration of the
             study.

         18. Discontinued use of Restasis within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny Asbell, • MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>April 29, 2011</results_first_submitted>
  <results_first_submitted_qc>July 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2012</results_first_posted>
  <last_update_submitted>July 20, 2012</last_update_submitted>
  <last_update_submitted_qc>July 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asbell, Penny, M.D.</investigator_affiliation>
    <investigator_full_name>Penny Asbell</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Dry Eye Disease</keyword>
  <keyword>DED</keyword>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>Omega-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omega-3 Supplement</title>
          <description>5 Gel Capsules to be taken orally daily to give a total dose of 2000mg EPA and 1000 mg DHA</description>
        </group>
        <group group_id="P2">
          <title>Olive Oil</title>
          <description>5 Gel Capsules of olive oil to be taken orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">2 withdrew from the study d/t adverse events. 1 had shortness of breath and the other had chest pain</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omega-3 Supplement</title>
          <description>5 Gel Capsules taken orally to achieve a daily dose of 2000mg EPA and 1000mg DHA</description>
        </group>
        <group group_id="B2">
          <title>Olive Oil</title>
          <description>5 Gel Capsules of olive oil taken orally daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="14"/>
                    <measurement group_id="B2" value="57" spread="15"/>
                    <measurement group_id="B3" value="56" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change on Ocular Surface Disease Index (OSDI)</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on Brief Ocular Discomfort Inventory (BODI)</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change on Impact of Dry Eye on Everyday Life (IDEEL)</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Associated With Chronic Pain</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Ocular Surface</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Schirmer’s</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Relevant Biomarkers: HLA-DR, MUC 5A, Cytokines</title>
        <time_frame>90 +/- 14 days following initiation of drug regimen</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content</title>
        <time_frame>Baseline and 3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Supplement</title>
            <description>5 Gel Capsules taken orally to achieve a daily dose of 2000mg EPA and 1000mg DHA</description>
          </group>
          <group group_id="O2">
            <title>Olive Oil</title>
            <description>5 Gel Capsules of olive oil taken orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in REd Blood Cell(RBC) Membrane Fatty Acid(FA) Content</title>
          <units>Percentage Total Fatty Acids</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eicosapentaenoic acid(EPA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="0.23" upper_limit="2.39"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.01" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>docosahexaenoic acid(DHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" lower_limit="-0.36" upper_limit="1.90"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-0.20" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachdinocic acid(AA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" lower_limit="-3.17" upper_limit="-0.97"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-0.84" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omega-3 Supplement</title>
          <description>5 Gel Capsules taken orally to achieve a daily dose of 2000mg EPA and 1000mg DHA</description>
        </group>
        <group group_id="E2">
          <title>Olive Oil</title>
          <description>5 Gel Capsules of olive oil taken orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal mass due to graft verus host disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>watery eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>DREAM: Feasibility Study, is labeled “feasibility” because its primary end-point is to demonstrate an ability to execute the protocol rather than generate statistically relevant data on the safety and efficacy of omega-3 EFA in patients with DED.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Penny Asbell</name_or_title>
      <organization>Mount Sinai School of Medicine</organization>
      <phone>(212) 241-7977</phone>
      <email>penny.asbell@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

